What does gain loss on priority review voucher mean?

The gain or loss recognized upon the sale or transfer of a Priority Review Voucher (PRV) granted by regulatory authorities. This reflects the monetization of intangible regulatory assets.

PTC Therapeutics PTCT Gain Loss On Priority Review Voucher

Gain Loss On Priority Review Voucher at other companies

Avis Budget GroupCAR

$10M+103%

WeyerhaeuserWY

$58M—

Fifth Third BankFITB

$9M-30.8%

SalesforceCRM

$558M+986%

ARE

Alexandria Real Estate EquitiesARE

$0-100%

Boston ScientificBSX

$158M+664%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:GainLossOnPriorityReviewVoucher.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's gain loss on priority review voucher.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's gain loss on priority review voucher?: PTC Therapeutics (PTCT) reported gain loss on priority review voucher of $24.98M in Q4 2024.
What does gain loss on priority review voucher mean?: The gain or loss recognized upon the sale or transfer of a Priority Review Voucher (PRV) granted by regulatory authorities. This reflects the monetization of intangible regulatory assets.